Latest Hotspot

Chimeric Therapeutics reports FDA's approval of IND application for CHM 2101, a new CDH17 CAR T cell treatment targeting advanced GI cancer

7 November 2023
4 min read

Australian cell therapy pioneer, Chimeric Therapeutics, has disclosed that the US FDA has given the green light to the IND submission for CHM 2101. This novel CDH17 CAR T cell therapy created by Chimeric is initially planned for usage in treating gastrointestinal cancers.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The firm intends to carry out a broad-based, openly labelled Phase 1A/B clinical trial into CHM 2101 for subjects with advanced stages of Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a third-generation, innovative CDH17 CAR T cell treatment developed to target CDH17. 

This is a cancer target linked with a dismal prognosis and metastasis in the most frequently occurring gastrointestinal tumours encompassing Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. The CHM 2101 clinical program builds on preclinical studies conducted by leading immunotherapy scientist Xianxin Hua, MD, PhD, and his team at the Abramson Family Cancer Research Institute at the University of Pennsylvania, with results published in the leading scientific journal, Nature Cancer in March 2022. 

These studies have shown that CHM 2101 has the ability to eliminate established tumours in seven types of cancer, without causing toxic damage to healthy tissues. Dr. Xianxin Hua, noted that the move from discovery of the CDH17 target and CAR T therapy in preclinical trials to initiating clinical trials in patients with GI-cancers and neuroendocrine tumours is exhilarating. 

The professor of Cancer Biology in Penn's Perelman School of Medicine stated, "This step is key in the formation of a completely new CAR T treatment for GI-cancers and neuroendocrine tumours, and offers new possibilities for patients who have become unresponsive to existing treatments." Upon the receipt of FDA IND clearance, Chimeric is set to launch a Phase 1/2 multi-location clinical trial for patients with advanced stages of Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. It is anticipated that the trial will commence patient recruitment in 2024.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 6, 2023, there are 10 investigational drugs for the CDH17 target, including 17 indications, 9 R&D institutions involved, with related clinical trials reaching 6, and as many as 4940 patents.

CHM 2101, a pioneering 3rd generation CDH17 CAR T, was birthed from the globally acclaimed cell therapy institution, the University of Pennsylvania. The initial indications of its potential were revealed in Nature Cancer in March 2022, showcasing complete removal of tumors in seven distinct cancer types. Presently, CHM 2101 is under preclinical investigation, and there are preparations underway for initiating a phase 1A clinical test on gastrointestinal and neuroendocrine tumours.

图形用户界面, 文本

描述已自动生成

The Evolving Competitive Landscape Behind Vyjuvek, the World’s First-ever Topical Gene Therapy
Bio Sequence
3 min read
The Evolving Competitive Landscape Behind Vyjuvek, the World’s First-ever Topical Gene Therapy
7 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Vyjuvek patent are Krystal Biotech with 32 applications, Holostem Terapie Avanzate Srl with 6 applications, and FONDATION A DE ROTHSCHILD with 2 applications.
Read →
Pilocarpine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
5 min read
Pilocarpine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
14 November 2023
This article summarized the latest R&D progress of Pilocarpine Hydrochloride, the mechanism of action for Pilocarpine Hydrochloride, and the drug target R&D trends for Pilocarpine Hydrochloride.
Read →
 Unleashing the Power of Perindopril Erbumine: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Perindopril Erbumine: A Comprehensive Review on R&D Breakthroughs
14 November 2023
This article summarized the latest R&D progress of Perindopril Erbumine, the Mechanism of Action for Perindopril Erbumine, and the drug target R&D trends for Perindopril Erbumine.
Read →
A Comprehensive Review of Pentostatin's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Pentostatin's R&D Innovations and Drug Target Mechanism
14 November 2023
This article summarized the latest R&D progress of Pentostatin, the mechanism of action for Pentostatin, and the drug target R&D trends for Pentostatin.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.